Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6018
    -0.0016 (-0.27%)
     
  • NZD/EUR

    0.5585
    -0.0009 (-0.16%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    79.00
    -0.26 (-0.33%)
     
  • GOLD

    2,370.90
    +30.60 (+1.31%)
     
  • NASDAQ

    18,122.62
    +9.16 (+0.05%)
     
  • FTSE

    8,438.20
    +56.85 (+0.68%)
     
  • Dow Jones

    39,432.97
    +45.21 (+0.11%)
     
  • DAX

    18,756.86
    +70.26 (+0.38%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7480
    -0.0200 (-0.02%)
     

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2021.

To access the conference call:

  • U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.

  • Participants should ask to be connected to the Editas Medicine earnings conference call.

A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

ADVERTISEMENT

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com